3章 有害性の同定
|
|
|
- しほこ りゅうとう
- 7 years ago
- Views:
Transcription
1 PDGF DEP DE F mg/m 3 DE LTB4 B6C3F1 Wistar 3.1mg/m 3 DE 24 ICR 3.0mg/m 3 DEP ICR mg DEP 10 NOS - O 2 NO ONOO - DEP DEP DE DEP Takano 1997 ICR 0.1mg DEP OA 1µg OA+DEP vehicle 330 OA 7 DEP IL-5 OA+DEP 8 IL-5 Th2 GM-CSF OA+DEP IL-4 IgE IgG1 8 Th2 IL-5 GM-CSF IgG
2 3-18 OA+DEP OA mg DEP Takano 1 / 6 ICR 14 IL IL-4 IgG1 8 (it)(1µg OA 3 1 it) (1997) IgE 0.1 mg DEP 1 / 6 ICR Rrs OA+DEP Takano (1µgOA 3 1 it) OA DEP (1998a) mg DEP C3H/He>BALB/c OA IgG1 C3H/He Miyabara (it) (1µg OA / 5 C3H/He BALB/c (1998a) it) IL-5 IL µg OA, 50µg DEP DEP 1 IgG1 1µg OA + 50µg DEP Ichinose 5 C3H/He> C57BL/6 >ICR >BDF/1 > CBA/2N (1997) (1µg OA 3 1 it) 12, OA OA+DEP C3H/He 1 mg/m 3,3 mg/m 3 (10µg OA ip DE 12 / C3H/He (Rrs) DE BALF Miyabara 1%OA /, 3 DE IgE,IgG1 (1998b) -SRBC IgM 7 / 0.35, 3.5, 7.1 mg/m 3 ( F-344 AFCs 3.5mg/m 5 / Bice SRBC CD-1 AFCs SRBC IgM, IgG, (1985) 6, 12, 18, 24 IgA 3 mg/m 3 12 / C3H/He (1µg OA 3 1 ip) 7 / 5 (Rrs) OA+DE Miyabara IL-5 (1998c) 3 mg/m 3 12 / ICR OA Miyabara (1µgOA 3 1 ip 7 / 6 OA+DE 3 7 IL-2 IL-5 (1998d)
3 3-18 0, 0.3, 1.0, 3.0 mg/m 3 OA+DE DEP (16 12 / 1.0 mg/m 10µg OA ip, 1 OA 3 Ichinose ICR 7 / mg/m 3 OA DE (1998) 3 1 0, 0.3, 1.0, 3.0 mg/m 3 (16 OA+DE DEP 12 / Takano 10µg OA ip, 1 OA ICR 3.0 mg/m 3 IL-5 IgG1, IgE 7 / 40 (1998b) 3 1 OA -SRBC IgM 7 / 0.35, 3.5, 7.1 mg/m 3 ( F-344 AFCs 3.5mg/m Bice 5 / SRBC CD-1 AFCs SRBC IgM, IgG, IgA (1985) 6, 12, 18, 24 3 mg/m 3 12 / C3H/He (1µg OA 3 ip) 7 /,5 (Rrs) OA+DE Miyabara IL-5 (1998c) 3 mg/m 3 (1µgOA / OA Miyabara ICR ip 7 / 6 OA+DE 3 7 IL-2 IL-5 (1998d) 0, 0.3, 1.0, 3.0 mg/m 3 OA+DE DEP (16 12 / 1.0 mg/m 10µg OA ip, 1 OA 3 Ichinose ICR 7 / mg/m 3 OA DE (1998) 3 1 0, 0.3, 1.0, 3.0 mg/m 3 (16 OA+DE DEP 12 / Takano 10µg OA ip, 1 OA ICR 3.0 mg/m 3 IL-5 IgG1, IgE 7 / 40 (1998b) 3 1 OA 3 mg/m 3 12 / 8 Hashimoto BALF (2001)
4 Takano 1998a Rrs OA DEP OA DEP DEP OA Miyabara 1998 IgG IgG C3H/He IgG high responder BALB/c IgG low responder 0.025mg DEP µg OA OA IgG1 C3H/He BALB/c 30 OA+DEP C3H/He BALB/c 4.6 OA+DEP C3H/He BALB/c 18 Rrs C3H/He OA+DEP 2 3 BALB/c Rrs OA DEP OA+DEP IL- 5 IL-2 C3H/He BALB/c 20 IgG1 IL-5 IL-2 Ichinose 1997 IgG mg DEP µg OA OA+DEP OA OA IgG1 IgG1 C3H/He C57BL/6 ICR>BDF1 CBA2N OA OA+DEP C3H/He IgG1 DEP IgE DEP IgE IgG1 DEP IgE NALT nasal-associated lymphoid tissue IgE IgG IgA Ohta 1999 DEP DEP A/J C57BL/6 2 DEP β2- DEP GM-CSFmRNA GM-CSF DEP IL
5 GM-CSF DEP DEP GM-CSF Walters 2001 BAL PM DEP 0.5mg 1 PM AHR BAL DEP BAL AHR AHR,BAL PM AHR 7 BAL 7 AHR Th2 IL-5, IL-13, Th1 PM AHR BAL PM Walters PM 2 DE Miyabara 1998a C3H/He 6 1mg OA / 5 DEP 3mg/m 3 DE OA 15 Rrs BALF OA DE / BALF DE OA+DE / BALF OA+DE 80 OA 4.4 OA+DE OA 66 6 Rrs OA+DE OA IgE IgG1 OA OA DE IL-5 IL-4 GM-CSF IL-2 OA+DE OA IL-5 IL-5 IL-2 IL-2 IgE IgG1 Miyabara 1998d ICR 1 12 DE 1mg OA / 5 DEP 3mg/m 3 DE OA 15 OA OA+DE 3 7 OA IgE
6 OA IgE IgG1 1 Miyabara 1998c C3H/He 10µg OA / 12 DEP 1mg/m 3 3mg/m DE OA 6 Rrs BALF DEP 1mg/m 3 3mg/m 3 OA Rrs DEP OA IgE IgG1 OA DE 30 1mg/m 3 3mg/m 3 C3H/HeN OA+DE IgE IgG1 Ichinose 1998 ICR / 34 DEP 0mg/m 3 0.3mg/m 3 1.0mg/m 3 3.0mg/m 3 DE 16 10µg OA 3 1 OA OA+DE DEP DEP 1.0mg/m 3 OA DE 2 DE 1mg/m 3 OA+DE 0.3mg/m 3 Takano 1998b Ichinose DE 6 40 DE Rrs Rrs OA DE 3.0mg/m 3 IL-5 DE 3.0mg/m 3 OA+DE OA 3.3 GM-CSF 3.0mg/m 3 OA 60 IgG1 10 IgE 10 DEP Hashimoto 2001 DE 3mg/m 3 DE OVA / 2 OVA DE DE IAR LAR
7 IAR DE BALF DE OVA DE LAR OVA DE BALF DE IAR DE LAR DEP OA DEP mg/m 3 DE 1 12 OA 3 OA DE DEP 1.0mg/m 3 OA DE 0.3mg/m DE 3-19 DEP DE Kobayashi 1995 DEP mg/kg DEP 1 3.2mg/m 3 DE 3 28 DE Kobayashi Hiruma mg/m 3 DE 28 DE Muranaka 1986 DEP IgE DEP DE
8 3-19 OA DEP BDF1 IgE DEP IgE Muranaka (1986) µg DEP ,5 25µg OA DEP 1µg OA 0.25µg Takafuji BDF1 IgE (1987) OA OA or DEP BDF1 IgE DEP IgE Suzuki (1993) 10µgOA 10µgOA or 1mg DEP IL-4 IL-4 Fujimaki 0.3mgDEP 3 3 T IgE BALB/c IgE (1994) OA IgE 1µgOA 1µgOA 5µgDEP 3 IL-4 OA DEP Fujimaki 3 BALB/c IFN-γ OA IgE (1995) DEP DEP mg/kg DEP DEP Kobayashi 30 Hartly (1995) mg/m mgdep 6.0 mg/m 3 OA IgE DE Fujimaki IL-4 IL-10 BALB/c IgE (1997) IFN-γ IgE IgG4 DEP mrna Th2 Diaz-Sanchez IgE IL-4 IL-5 IL-6 IL-10 IL-13 Th1 (1997) IFN-γ IgE DEP IgE Maejima 2 BDF1 (1997) 2 1 IgE DE DEP OA
9 mg/m 3 3 DE DE Kobayashi Hartly (1997) mg/m mg/m 3 28 DE DE 4 Kobayashi Hartly (1998) DE Hiruma Hartly (1999) 30µg 30µg IgE IL-2 IL-4 DEP IgE Ohyama DEP100µg 2 10 BALB/c (1998) 10 1mg keyhole limpet hemocyanin (KLH) KLH mg KLH KLHIgE DEP DEP Diaz-Sanchez KLHIgE (1999) KLH mg DEP DEP IL-8 Terada DEP IL-8 GM-CSF GM-CSF mg/m 3 DE (OVA) 0.3mg/m 3 DE mg/m 3 DE Kobayashi IgG Hartly IgG IgE 1.0mg/m 3 (2000) IgE DE DE DEP OA
10 Takafuji 1987 DEP µg OA µg DEP 1µg OA 0.25µg OA IgE DEP Suzuki 1993 DEP OA OA OA IgE Fujimaki DEP DEP T Th1 TH2 IgE DE 6mg/m 3 DE DEP Ohyama 1998 OA 30µg 100µgDEP Fujimaki DEP Maejima DEP IgE Diaz-Sanchez p.106 Fujimaki Kobayashi mg/m 3 DE OVA 1 1 IgG IgE 0.3mg/m 3 DE IgG IgE 1.0mg/m 3 DE mg/m 3 DE Terada 1999 HNECs HMMECs H1 H1R IL-8 GM-CSF DEP DEP DE HNECs HMMECs HNEC HMMEC DEP H1RmRNA RT-PCR DEP HNEC HMMEC DEP 3 24 PBS mol/l 24 IL-8 GM-CSF ELISA DEP HNECs HMMECs H1R mrna
11 IL-8 GM-CSF DEP HNECs HMMECs DEP IL-8 GM-CSF HNECs HMMECs DEP IL-8 GM-CSF mg/m 3 DEP DE DEP mg/m 3 DE DE DEP 0.4mg/m 3 DNA -6- DE 7 20 / / mg/m 3 Lewis mg/m 3 Mauderly 1987a Research Committee for HERP Studies mg/m 3 Barnhart
12 3-20 mg/m 3 mg.h/m ,520~2, , , , ,240 12, ,380-18, , , a 0.4 a 1.1 a 2.3 a 3.7 b 1,592 15,925 31,850 7,400 21,800 61,700 35,500-NMRI 38,300-C57 1,373 5,117 13,478 28,829 46, / 7 / / 5 / 104 F344 A/J Cyrian Kaplan (1982) Lewis (1989) 7 / 5 / Bhatnagar (1980) F Pepelko (1982a) 8 / 7 / SD Bhatnagar (1980) 39 A/HEJ Pepelko (1982a) 8 / 5 / Chinese Pepelko (1982b) / 5 / 120 Cyrian Heinrich (1982) 6 / 5 / Wistar Karagianes (1981) 87 8 / 7 / 104 F344 Iwai (1986) 7 / 5 / / 5 / / 5 / 13.5 NMRI 24 C57BL/N 16 / 6 / 130 a Light-duty engine b Heavy-duty engine F mg/m 3 7.0mg/m 3 7.0mg/m 3 Mauderly (1987a) CD-1 Henderson (1988) Wistar NMRI Heinrich (1995) 7 mg/m 3 NMRI Heinrich (1995) C57BL/N F Research Committee mg/m3 for HERP studies (1988)
13 Kato 1999 DE DE ppm mg/m 3 H 3ppm 3mg/m 3 M 1 ppm 1mg/m 3 L 0.2 ppm 0.2mg/m 3 3 M MG 1 ppm 0mg/m L M MG MG 2 L MG 3 H M 24 H 12~24 12 L M MG M 24 MG DE DEP DE 24 DEP Nagai 2000 H 3ppm 3mg/m 3 M 1 ppm 1mg/m 3 L 0.2 ppm 0.2mg/m 3 DE M MG 1 ppm 0mg/m MG M DE
14 DE 0.4mg/m 3 DE 7 20 / / mg/m mg/m mg/m DE 3-21 Campbell CR/CD-1 20 DE DE /46 TSP 6.4mg/m 3 NO 2 2.8ppm Streptococcus pyogenes A/PR Streptococcus pyogenes A/PR8-34 Hahon 1985 CD-1 2mg/m 3 2mg/m 3 DE 1mg/m 3 DE 1mg/m DE DE 6 Lewis 1989 DE CD-1 7 / 5 / mg/m 3 2mg/m 3 DE 1mg/m 3 DE 1mg/m 3 4 DE
15 3-21 6~7mg/m 3 2, 6 8 / 8, 15, 16 8 / 44~46 Streptococcus p. Campbell (1981) CR/CD-1 2mg/m 3 2mg/m 3 DE 1mg/m 3 + 1mg/m 3 DE 7 / 5 / 1, 3, 6 IFN Hahon (1985) CD-1 2mg/m 3 2mg/m 3 DE 1mg/m 3 + 1mg/m 3 DE 7 / 5 / 24 DE Lewis (1989) CD-1 IFN
16 DE 3-22 Dziedzic mg/m 3 DE 0.2µm 4 8 T B Mentnech 1984 F-344 2mg/m 3 2mg/m 3 DE 1mg/m 3 DE 1mg/m SRBC phytohemagglutinin PHA concanavalin A Con A Bice 1985 DE F-344 CD mg 3.5mg 0.35mg/m 3 MMAD µm SRBC 7mg/m 3 3.5mg/m mg/m 3 3.5mg/m 3 IgM IgG IgA Fujimaki 1997 IgE mg/m 3 DE 3 OA 3 3 OA IgE 6.0mg/m 3 OA 6.0mg/m 3 IL-4 IL-10 IFN-γ DE IgE DEP DEP 3-23 Muranaka 1986 DEP BDF1 5 DEP OVA; DNP OVA :JCPA IgE PCA DEP µg/mouse 52 1µm DEP IgE DEP 1~1000µg DEP 10~100µg
17 3-22 (mg/m 3 ) µmMMD 20 / 5.5 / 4, 8 Dziedzic (1981) µmMMD 7 / 5 / 52, 104 F344 SRBC PFC PHA, ConA Mentnech (1984) µmMMD 7 / 5 / mg/m 3 7.0mg/m 3 F344 Bice (1985) CD-1 SRBC µm 12 / 7 / 3 6mg/m 3 BALB/C IL-4, IL-10 IFN-γ OVA IgE Fujimaki (1997)
18 3-23 DEP ,000µg/mouse 5 BDF1 IgE Muranaka (1986) DEP 1mg/mouse 1mg/mouse 6 BDF1 DEP, IgE Suzuki (1993) 0.3mg/mouse 3 BALB/C IL-4 0.1mg/mouse BALB/C OVA IgE Fujimaki (1994) Løvik (1997) µg/mouse 5 DBA/IJ HEL Yoshino (1999) DTH µg/mouse µg/mouse 10 5 DBA/IJ CII IFN-γ, IL-2, IL-4 DBA/IJ HEL,IgG1,IgG2a, IL-4, IFN-γ 1.0mg/mouse BALB/C IL-4 CD4 Yoshino & Sagai (1999) Yoshino&Sagai (1999b) van Zijverden (2000a) 1.0mg/mouse BALB/C TNP-OVA IgE,IgG1 van Zijverden &Granum(2000b)
19 Suzuki 1993 BDF OVA 2 OVA 3 OVA DEP OVA IgE OVA DEP 1 10µg JCPA 2 10µg JCPA JCPA IgE DEP IgE Fujimaki 1994 DEP IgE BALB/c DEP OA OA DEP+OA IL-4 OA IgE DEP+OA Løvik 1997 BALB/c 8 DEP CB DEP 0.03µm 0.1mg/ OVA 20 DEP+OVA 4 6 CB OVA DEP OVA IgE DEP+OVA DEP CB CB DEP DEP Yoshino 1998 DEP DBA/1J 5 8 hen egg lysozyme HEL 10mg µg DEP 0.4µm HEL HEL IgG1 IgG2a HEL HEL mg DEP DEP IL-4 IFN-γ DEP DEP Yoshino Sagai 1999 Collagen-induced Aryhritis DEP DBA/1J 5 type C complete Freund`s adjuvant 21 DEP mg/ml 50µl PBS 2 20 Collagen-induced Aryhritis
20 DEP C IgG IgG2a DEP C DEP IFN-γ IL-2 IL-4 Collagen-induced Aryhritis DEP DEP carbonyl iron chrysotile asbestos crocidolite asbestos iron-coated chrisotile asbestos fiberglass wollastonite fiber Warheit 1988 DEP Kanemitsu 1998 DEP Yoshino Sagai 1999 DEP DBA/1J HEL DEP HEL IgG1 IgG2a IFN-γ IL-4 Th1 Th2 DEP van Zijverden 2000a BALB/c DEP <0.5 mm CBP <0.5 mm SIP 1~5 µm 1mg TNP-OVA DEP CBP IL-4 4 DEP IgG1 IgE CBP IgG1 IgE IgG2a SIP IgG2a Th1 Th2 van Zijverden Granum 2000b BALB/c NIH/Ola DEP CBP SIP TNP-OVA PSP 0.2µm OVA SIP Th1 DEP Th2 CBP PSP Th1/Th2 Granum 2001a 0.1 µm PSP 6~8 NIH/Ola OVA IgE IgE PSP PSP Grunum 2001b
21 IgE 0.5 µm PSP 0.05~0.5 µm polytetrafluoroethylene 0.2 µm 4 OVA NIH/Ola IgE IgG2a IgE DE 3-24 Penney DE DE µg/m 3 20 / 5.5 / µm 2 13 Karagianes 1981 Wistar DE 6 / 5 / 20 DE 8.3mg/m 3 6.6mg/m mg/m 3 DE 8.3mg/m 3 5.8mg/m 3 DE 0.71µm MMAD 2.1µm MMAD CO 4 DE 3.7% 20 5% 4 4.1% % Heinrich 1982 Syrian Golden 3.9mg/m 3 MMD 0.1µm DE GOT LDH AP Brightwell 1986 F mg/m DE AP γ-gtp 2mg/m 3 DE DE 3.5mg/m 3 DEP DEP PAH,
22 3-24 (mg/m 3 ) µm MMD 8.3 (0.71µm MMD) 6.6, 14.9 (2.1µmMMD) DE / 5.5 / 78 6 / 5 / 78 F344 Penney (1981) Hartley Karagianes (1981) Wistar COHb 4~5% µm MMD 7-8 / 5 / 29 Syrian GOT, LDH, AP, Heinrich (1982) / 5 / 104 F344 AP γ-gtp, Brightwell (1986)
23 IgE IgG2a IgE 3.9mg/m 3 DE DE 3-25 DE Wiester 1980 Hartley 20 / 7 / 6mg/m 3 DE 8 DE 2 Brightwell 1986 F / 5 / mg/m 3 DE 2 6.6mg/m 3 / Kaplan 1982 Penney 1981 Green 1983 Vallyathan 1986 F344 Hartley DE DE F344 Hartley 6 7mg/m 3 / / DE 3-26 Lee 1980 SD 13 DE 20 / 42 aryl hydrocarbon hydroxylase AHH EH AHH EH DE 14.2ppm DEP NO X Pereia 1981 DE DEP 6mg/m 3 DE A Y Pepelko Peirano 1983 CD mg/m
24 3-25 mg/m DE 6.8 DE Hartly Wiester (1980) DE 1.5 F A/J 6 Cyrian Kaplan (1982) F344 Hartly Penney (1981) F344 Green (1983) F mg/m3 Brightwell (1986) F344 Vallyathan (1986) DEP dimethyl sulfoxide Hartley Minami (1999)
25 ppm 6mg/m /, 42 8 /, mg/m 3 LD *1 8 /,7 / 3-26 SD 10 Aryl Lee 1980 hydrocarbon hydroxylase 4.5 A Pereia(1981) CD-1 Pepelko Periano 100 (1983) 6 mg/m 3 8 /,7 / T Pepelko Periano 7 (1983) 50, 100, 200mg/kg B.W 5 C57BL/6 6 mg/m 3 (HD) *2 8 /,7 / Quinto DeMarinis C3H (1984) SD Pepelko Periano (1983) mg/m 3 7 /,5 / F-344 Lewis (1989) 2 mg/m 3 7 /,5 / 6 2 Lewis (1989)
26 ng/µl DEP Fredericson 25 (1993) 1/10 MCF-7 DEP Ah Meek(1998) 5.63 mg/m 3 6 /,5 /, 19 Watanabe (NO ppm 3 Onuki(1999) NO 8.10ppm) 19 (FSH) 0.3, 1.0, 3.0 mg/m 3 12 /,7 /, TCR 0.3 mg/m 3 Yoshida (1999) 10 6 (6 ) LH mrna 5.63 mg/m Watanabe N ( 20 ) DEP (2001) *1,LD light duty engine *2,HD heavy duty engine
27 DE 8 / 7 / Lewis 1989 F-344 DEP 2mg/m 3 DE 7 / 5 / Pepelko Peirano mg/m 3 DE T / 7 / 7 Quinto De Marinis 1984 DEP kg mg 5 C57B1/6 C3H 1 F 1 200mg 8 Lewis cynomolgus monkey DEP 2mg/m 3 DE 7 / 5 / 2 motility Pepelko Peirano mg/m 3 SD 8 / 7 / Fredericsson 1993 DEP 25% 5 DEtHxP DmeP DEP 1/10 1/ DEP Meek 1998 DEP DEP-E Ah ER DEP-E Ah DNA 22 DEP-E ER E2 DEP-E AhR ER DNA
28 Watanabe Oonuki 1999 DE 5.63mg/m 3 4.1ppm NO ppm NO FSH 3 FSH DE DE Yoshida 1999 DEP mg/m 3 DE ICR Fredericson 1 DE mg/m 3 29 DE LH mrna DEP LH 6 12mg/m 3 U Watanabe 2001 Fisher DE, NO 2, NO 5.63mg/m 3, 4.10ppm, 8.10ppm DE DEP DE DEP Taneda 2000 DEP DEP 20µg/ml
29 DEP 1M 20µg/ml DEP DEP 0.3mg/m 3 12mg/m 3 DEP DE DEP, DEP DE 3-27 Laurie mg/m 3 DEP DE / 15 Laurie mg/m 3 DEP DE Laurie mg/m 3 DEP DE Laurie / mg/m
30 3-27 (C) C T (mg/m 3 ) (T) (mg.h/m 3 ) NO 2 (ppm) SO 2 (ppm) CO (ppm) 6 20 /, 7 /, 6 5, SD, Laurie (1978) 6 8 or 20 / 7 /, 1,008~13, ,4,6 or 16 SLA 20 8 / SD, SLA 20 Laurie (1980) /
31 DE DEP IgE IgE IgEmRNA IgE IgG4 Th2 Th1 DE 0.3mg/m 3 DE 1 B CD4+T CD8+T DE DE DE DE DE DE DE DE
32 20m m 1 DEP DEP DE SPM PM 10 PM 2.5 DEP PM 2.5 PM 10 DE DE mg/m 3 DE 1.5mg/m
33 DE 6mg/ m mg/ m 3 DEP DE 7 / 5 / mg/m 3 DEP DE 1.5mg/m 3 DEP DE / 5.5 / 40% 20%FVC FEV mg/m 3 DEP DE 7 / 5 / 104 7,280mg h/m 3 25% ventilation distribution mg/m 3 DEP DE DEP PAH DEP IgE IgE DEP DEP DE F mg/m 3 DE LTB4 B6C3F1 Wistar 3.1mg/m 3 DE 24 ICR 3.0mg/m 3 DEP ICR mg DEP
34 - O 2 NO ONOO - DEP NOS DEP OA DEP OA DE OA OA+DE DEP 1.0mg/m 3 DE HNECs HMMECs DEP IL-8 GM-CSF mg/m 3 DEP DE DEP mg/m 3 DE mg/ m 3 DEP DE
35 DNA -6- DE 7 20 / / mg/m mg/m mg/m 3 DE 2 3.9mg/m 3 DE IgE IgG2a IgE DE F344 Hartley 6 7mg/m 3 / / DE DE DE ICR mg/m 3 DE 12 / LH 12mg/m 3 DE DEP DEP
36 6mg/m 3 DE DE
14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
- 108 -
3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg
レイアウト 1
1 3 6 7 8 3 6 7 8 g mg 6 1 16 16 18 16 13 138 13 16 1 11 8 78 8 17 9 9 g mg 18 13 1 1 1 99 6 3 36 3 3 8 1 18 18 18 16 16 1 1 g mg 1 1 13 13 1 11 11 g mg 8 6 g 1 g mg 93 38 9 93 8 8 176 1 1 1 1 11 18
CSR報告書2005 (和文)
A 250 200 150 100 50 0 25,000 20,000 15,000 10,000 5,000 0 1,000 800 600 400 200 0 168 14 14 27 54 60 2000 16,975 1,314 1,207 8,977 5,477 2000 698 112 115 292 178 2000 223 24 28
ブック 1.indb
21 1211 27 11 27 12 16 20 11 27 10 20 28 29 30 12 10 11 12 30 13 30 14 10 30 15 11 16 12 17 13 18 14 19 15 20 16 10 21 11 27 106 21 107 108 109 110 21 111 28 112 28 10 113 29 11 11421 30 12 11521 32 13
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
( 50kg 26 (22
2 ( 50kg 26 (22 50 3 ( 50 WHO (27 101 1967 1968 1970 1970 Cd, Cu, As 1991 2002 1968 1970 Cu, Cd, As) 1975 1984 Hg, Cd 1986 1991 1992 1994 5 1994 1999 1999 2002 (2003 1975 1980 1985 1990 1995 1998 (26
2
2. 1 2 3 Heavy Duty Vehicle Light Duty Vehicle 4 Light Duty Vehicle Heavy Duty Vehicle CO 2000 NOx PM 2010 1AOP1 1996 18 Commission 1997 1 1998 5 2000 2005 OBD 2000 2003 2005 Heavy Duty Vehicle 1997 12
! & # # w w w w w w w w l & w_ # w_ w # w w w # w w # w w # w w w w bw w bw w bw w w bw w b w w_ l !!!!!! 6!!!! 6 ' ' ' ' ' ' ' ' ' ' ' '! ' ' ' ' ' ' ' ' ' ' ' ' ' '! ' ' ' ' ' ' ' ' ' ' '
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
●70974_100_AC009160_KAPヘ<3099>ーシス自動車約款（11.10）.indb
" # $ % & ' ( ) * +, -. / 0 1 2 3 4 5 6 7 8 9 : ; < = >? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y " # $ % & ' ( ) * + , -. / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B
Ⅰ 調査研究の概要
1999 IP 2005 6 IT IC 2005 3 . 1-1. 1-2. 1-3.. 2-1. 2-2. 2-3. 2-4. 2-5. 2-6. 2-7... 1 2 3 1 4 5 6 TCA 7 8 9 10 11 12 13 14 15 16 17 MCF 2004 18 19 MCF 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
untitled
1.4 特 許 状 況 - 1 - - 2 - 1.5 起 原 又 は 発 見 の 経 緯 及 び 開 発 の 経 緯 FCT CT RH ... 1.5-1... 1.5-1... 1.5-1... 1.5-1... 1.5-2... 1.5-2... 1.5-2... 1.5-3...1.5-4... 1.5-5 i 10mg FCT 1 1 6 15 5mg CT 1 1 2 6 4mg CT
PM µm PM CLRTAP 13 EANET SPM 10 µm µm PM2.5 PM2.5 SPM 1997 PM2.5 PM2.5 PM2.5 PM2.5 PM2.5 SPM PM2.5 PM2.5 PM2.5 PM2.5 PM2.
PM2.5 2.5 µm PM2.5 1950 1979 CLRTAP 13 EANET2001 1972 SPM 10 µm µm PM2.5 PM2.5 SPM 1997 PM2.5 PM2.5 PM2.5 PM2.5 PM2.5 SPM PM2.5 PM2.5 PM2.5 PM2.5 PM2.5 PM2.5 PM2.5 15 2 Particulate Matter; PM 2.5 µm PM2.5
抗アレルギー効果のあるKW乳酸菌の発見と活用
KW3110 3 1 90 1983 6 1998 20 1989 Strachan BCG Lactobacillus Lactococcus Streptococcus Lactobacillus casei brevis johnsonii Th2 Th2 IL 4 B IgE IgE IgE IL-12 IL-12 Th1 Th1 Th2 Th2 Th1 Th2 KW 101 Th1/Th2
untitled
280 200 5 7,800 6 8,600 28 1 1 18 7 8 2 ( 31 ) 7 42 2 / / / / / / / / / / 1 3 (1) 4 5 3 1 1 1 A B C D 6 (1) -----) (2) -- ()) (3) ----(). ()() () ( )( )( )( ) ( ) ( )( )( )( ) () (). () ()() 7 () ( ) 1
- 1 - - 2 - 320 421 928 1115 12 8 116 124 2 7 4 5 428 515 530 624 921 1115 1-3 - 100 250-4 - - 5 - - 6 - - 7 - - 8 - - 9 - & & - 11 - - 12 - GT GT - 13 - GT - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - -
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 13,996t 0% 2,379.3t 17.0% 4,630t 0% 532.4t 11.5% 72.9% 96.6% 3,000t 2.9% 3,000t 100.0% 20t BDF 75.0% 18t 90.0% 1,053t 1,053t 100.0% 1,068t 19.9% 854t 80.2% 670t 21.8% 670t
10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2
橡96-01.PDF
1 961 31 CAS 71432 C 6 H 6 78.11 1) 99 % 1. 5.5 2) 80.1 2) -11 3) 293563 3) 1.48.0% 3) d 20 0.8786 4) 2.77 ( = 1) 4) 4 13.33 kpa (100 mmhg) (26.9) 2) log Pow2.13 ( ) 5) 2.14 ( ) 6) m/z78 ( 1.0 )77 ( 0.20
160mm OR16-34 ORB16-34 OR16-35 ORB16-35 OR16-43 ORB16-43 OR16-44 ORB16-44 OR16-45 ORB16-45 OR16-46 ORB16-46 OR16-47 ORB16-47 OR16-48 ORB16-48 OR16-53
IP44 120mm OR12-33 ORB12-33 OR12-34 ORB12-34 OR12-35 ORB12-35 OR12-36 ORB12-36 OR12-43 ORB12-43 OR12-44 ORB12-44 OR12-45 ORB12-45 OR12-46 ORB12-46 OR12-47 ORB12-47 OR12-48 ORB12-48 OR12-49 ORB12-49 OR12-53
untitled
6 ( ). 1.. 1. 2. 3. 4. 5. ( ) 6. 7. 8. . 1. 1) 1 (12 3 ) 2 2) 3) ( ) ( ) 4) 2 () 2 2 3 5) ( ) R-Book ATLAS () 8 12 7 18 14 16 10 21 14 23 16 18 16 18 12 25 4 14 21 1 4 2 3 4 4 1 2 7 5 1 2 5 7 9 1 1 5 5
IP S ( :H ) ( ) ( :H22 4
90 30 440 8515 4 101 0532 54 5111 0532 53 1379 IP 1. 2. 3. 11 1 1. 2. 12 0 1 2 3 8 0 8 0 8 S 5 5 0 5 2 1 13 0 5 0 4 (:H22 4 28 ) 1 1 0 5 () (:H22 4 28 ) 1 2 5 0 (: ) ー (: ) ー1 0 0 0 0 (: ) 1/26 50P7 21
% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
香南市・香美市のニラ
ROTTLER Chinese chives Alliaceae Allium 133 33 33 33 133 41 36 12 1 ha2 3 JA 4 1 H17 23 2010 4 JA 22 40,000~50,000 10a 4 100 5 120 6~8 120~150 20,000~30,000 10a 810 30 911 47 40 123 50 10a kg 4,000kg
19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
untitled
Cd: cr : 2MG: 2-1MG: 1- RBP: 1.8 2.8 20 5.2 5.2.1 WHO 5.2.1 1 298 g/l 5 g/l Peplow D, Edmonds R. 230mg/kg 2.5mg/kg 246µg/L 161µg/L Lee JS, 2005 5.2.1 11-19 µg/ 0.17-0.30 µg/kg / PTWI 17-30% 0.5µg/ 0.02µg/
136 pp p µl µl µl
135 2006 PCB C 12 H 10-n Cl n n 1 10 CAS No. 42 PCB: 53469-21-9, 54 PCB: 11097-69-1 0.01 mg/m 3 PCB PCB 25 µg/l 136 pp p µl µl µl 137 1 γ 138 1 γ γ γ µl µl µl µl µl µl µl l µl µl µl µl µl l 139 µl µl µl
A B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
untitled
1% 1 mg 1 mg 2 CTD 6 Section 2.6.1 Introduction 2.6.1 H 1 descarboethoxyloratadinesch 34117 7.9 SCH 34117 2.6.1-1 O OC 2 H 5 Cl N N JAN Loratadine (JANINN) ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]
(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
idwr2008_21
VanC 521 0.63 0.24 2.12 2.27 1.07 0.98 1.75 0.70 27.24 0.76 1.16 0.35 1.26 0.71 2SD 1SD 1SD 2SD A SD 0.21 0.58 3.02 7.02 1.89 0.70 0.20 0.72 0.11 0.37 0.43 0.04 0.79 0.39 5515 6.19 Streptococcus pyogenes
1 1 2 65
3 3 2000 6 14 2 30 4 2 1 1 2 65 1!?? < > 3 2 2 100 19 19 100 100 100 < > 19 2 2 2 2 < > 2000 2000 50 1945 5 50 1945 5 45 20 20 4 1945 4 5 5 5 100 50 20 5 2 20 5 20 5 5 6 20 6 19 5 5 6 5 6 2 20 6 21
取扱説明書 [F-08D]
![取扱説明書 [F-08D]](/thumbs/48/23832237.jpg "取扱説明書 [F-08D]")
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 22 a c b d 23 24 a b c a b c d e f g a b j k l m n o p q r s t u v h i c d e w 25 d e f g h i j k l m n o p q r s
14 4 12 10 8 6 3 2 4 2 1 0 0 100200300400500600 100200300400500600700 0 0 100200300400500600 100200300400500600700 (ppm) (ppm) 7 4 6 5 4 3 3 2 2 1 1 0 0 100200300400500600 100200300400500600700 0 0 100200300400500600
untitled
b 0 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01% 0.1% 1% 10% 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01% 0.1% 1% 10% 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01%
ニュースレター10-1.indd
The Japanese Society of Immunotoxicology 101192005 aaaa 12 2005172021 1-1-1 Tel. 03-5841-8205 / Dr. R.H. Pieters () "Immunotoxicology of therapeutics associated with allergy and autoimmunity" 2005 In
橡96-07.PDF
1 967 2482 CAS 50000 CH 2 O 30.03 2952% 12.5 % 1. 2) -92 2) -19.5 2) 5085 3) 424 3) 7.073.0% 4) 20 d 4 0.815 5) 1.03 ( = 1) 5) 1.33 kpa (10 mmhg) (-88.0) 2) log Pow0.35 ( ) 6) 0.35 ( ) 7) 1) m/z 29 ( 1.0
20 12 3 3 21 1 3 3 21 20 21 12
20 12 3 3 21 1 3 3 21 20 21 12 1 4 9 9 18 22 24 27 27 34 43 45 48 48 55 57 63 70 72 77 77 80 82 85 90 90 92 99 106 108 115 123 129 137 142 143 147 149 151 152 153 154 eco-t 10 20 12 15 15 28 38 66 71 91
フタル酸ジペンチル
147 148 Wistar- Hannover BrlHan: WIST@Jcl (GALAS) 30 100 12 6 0 20 0 20 0 2 10 50 250 µg/kg/day 1 ml/kg/day 1 1 g/kg/day ml/kg/day 8 2 1 1 1 AGD 4 21 2 2 SD 2 2 13 149 g/kg/day mg/kg/day 10 50 250 1,000
ステロールの用途について
* * (%) ( ) ( ) ( ) ( ) 54.1 52.3 60.3 18.1 27.6 17.2 15.2 0.5 6.3 0.0 13.8 0.0 12.6 5.8 16.2 (g / kg) 4.6 6.9 9.7 1 * ( ) () 250 mg /3/ 750 mg / 3 23 g/ 30 125250 mg/ 5 ( ) 6 ( 7 (Moducare ) $ ) 8 60
ニトロトルエン
4-115 116 4-3 2 117 4- g/kg/day mg/kg/day 25 125 30 40 50 100 250 300 ( ) ( ) ( ) ( ) F1 42 10 118 ER 10-11 M 1% 10-11 10-4 M ER 10-4 M 3% 10-11 10-4 M E-screen 10-9 10-4 M AR ( ) 10-6 10-4 M AR ( ) 10-6
2つの疑問
Daiichi College of Pharmaceutical Sciences 22-1 Tamagawa-cho, Minami-ku,Fukuoka 815-8511, Japan 1. B 10 14 2 2. 1. 2. 3. G. Edelman 3. H (heavy chain) L (light chain) 2 4 S-S R. Porter papain) N Fab(Fragment
untitled
ver. 3.3JT EVENING PRIMROSE EXTRACT 1 - PMS 1 2 1 4 Oenothera laciniata Oenothera striata Oenothera biennis Oenothera erythrosepala - 2 80 60 40 20 0 1. 2 3 PGGPAC 2. 3 4 ESR3.5 10 5 /g 4 3 1 Helicobacter
_4th2..
01-07 章 _4th2 了 18.8.25 6:46 PM ページ 110 110 2060 1569 2059201510 01-07 章 _4th2 了 18.8.25 6:46 PM ページ 111 111 43 26 548 795 254 1 3,686 443 283 1,668 4,129 915 6,712 2710 2730 2710 65 201729 20166,712 3,3834,081
untitled
1 2 1 2002 8 1 2003 11 1 152 2003 11 2 21 53 2003 12 24 4 54 2004 3 22 55 2004 4 9 56 2004 4 15 41 2004 4 15 2004 5 12 2004 5 19 2004 5 20 5 2004 12 16 58 2 2005 1 25 2005 8 23 5962 2005 8 26 2005 9 1
各位 平成１７年5月13日
9000 1 6 7 8 8 9000 1960 1 2 2 3 3 1471 4 1362 5 2006 6 7 8 1967 9 1988 1988 10 1000 1348 5000 3000 2 11 3 1999 12 13 14 9000 A 15 9000 9000 9000 10000 16 6000 7000 2000 3000 6800 7000 7000 9000 17 18
PAXgene Tissue DNA Kitプロトコールとトラブルシューティング(2301605 06/2009)
January 2009 PAXgene Tissue DNA Kit PAXgene Tissue Containers DNA PAXgene Tissue Container PAXgene DNA 3 PAXgene DNA 6 PAXgene DNA 9 13 2 PAXgene Tissue DNA Kit 01/2009 PAXgene DNA DNA PAXgene Tissue Containers
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
センター長
Techno Center News 6 No.6 1. 2. 3 4 5 6 8 3. 9 10 10 10 4. Origin 11 5. 16 8 2 14 3 4 5 14 100 8-1 - No.6 21 PAH CO 2 NO x PAH PAH: Polycyclic Aromatic Hydrocarbons PAH PAH - 2 - s 0.0003-110dB - 3 - No.6
参考資料５ 農薬評価書 メタアルデヒド（食品安全委員会資料）
1 3 3 4 5. 6 1. 6 2. 6 3. 6 4. 6 5. 6 6. 6 7. 6. 7 1. 7 2. 8 (1) 8 (2) 9 (3) 9 (4) 10 (5) 10 3. 11 (1) 11 (2) 11 (3) 11 (4) 12 4. 12 (1) 12 (2) 12 (3) 13 5. 13 6. 13 7. 14 8. 15 9. 16 10. 16 (1) 90 16-1
3, ,104 t mg/l 30 mg/l BOD mg 14 C 8, /kg 11 8, 1 11 OH = cm 3 / sec 11 OH /cm ppm
3, 3-1 200019 4800 CAS 91941 1138 3, 3-4, 4 - -3, 3 - H 2 N Cl Cl NH 2 C 12 H 10 C l2 N 2 253.13 1 95 1. 2 3, 4 132-133 402 5 >200 5 700kg/m 3 5 8.73 = 1 5.610-8 kpa 4.210-7 mmhg20 4 6 log Pow3.51 3.57
<8E9197BF8252817C825192E1977097CA93C590AB926D8CA92E786C73>
動 物 種 系 統 性 動 物 数 / 群 (DBA/1J 雌 7-9) (ICR) (Swiss 雄 方 法 ( 溶 媒 :1%エタ ノール) 期 間 雌 に17 日 間 し 交 配 させ 児 を 観 察 4 週 間 雄 に30 日 間 し 未 の 雌 と 交 配 ビスフェノールAの 低 用 量 毒 性 知 見 量 (mg/kg 体 重 / 日 ) 0.003 0.03 0.3 3 0.015 1.5
... 3... 3... 3... 3... 4... 7... 10... 10... 11... 12... 12... 13... 14... 15... 18... 19... 20... 22... 22... 23 2
1 ... 3... 3... 3... 3... 4... 7... 10... 10... 11... 12... 12... 13... 14... 15... 18... 19... 20... 22... 22... 23 2 3 4 5 6 7 8 9 Excel2007 10 Excel2007 11 12 13 - 14 15 16 17 18 19 20 21 22 Excel2007
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
*p145-174_Œâ‡í‡ê‡é
*p145-174_ 問 われる 09.1.16 10:34 PM ページ145 2007 200708 146 147 a s 148 a s d f g 153 a s d 158 a s d f g h j 166 a s d f 171 2009 145 *p145-174_ 問 われる 09.1.16 10:34 PM ページ146 45 2007 2008 146 *p145-174_
2 of 46 07.2.10 4:30 PM
1 of 46 07.2.10 4:30 PM 2 of 46 07.2.10 4:30 PM 3 of 46 07.2.10 4:30 PM 4 of 46 07.2.10 4:30 PM 5 of 46 07.2.10 4:30 PM 6 of 46 07.2.10 4:30 PM 7 of 46 07.2.10 4:30 PM 8 of 46 07.2.10 4:30 PM 9 of 46 07.2.10
橡フタル酸ブチルベンジル.PDF
1 97 7 3 1312 CAS 85 68 7 O BBP 1, 2- C 19 H 20 O 4 312.4 C C O O O (CH 2 ) 3 1 99.9 % 1. 2-35 3 2, 3 370 3, 4 199 d 25 4 1.117 2 10.8 = 1 5 1.15 10-3 Pa 8.6 10-6 mmhg 20 5 253 Pa 1.9 mmhg 200 5 log Pow
2
1 2 10 14 945 3000 2012 3 10 4 5 6 7 8 9 10 11 12 2011 11 21 12301430 (1215 ) 13 6 27 17 () ( ) ( ) (112360) 2 (1157) (119099) ((11861231) )( ) (11641205) 3 (1277) 3 4 (1558) (1639)() 12 (1699)( ) 7 (1722)
橡99-24_00 アリルアルコール.PDF
1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log